Evidence map›Paper›PMID 27514505›Full record

ArticleCancer gene therapy2016

Coinhibition of overexpressed genes in acute myeloid leukemia subtype M2 by gold nanoparticles functionalized with five antisense oligonucleotides and one anti-CD33(+)/CD34(+) aptamer.

M A Zaimy, A Jebali, B Bazrafshan, S Mehrtashfar, S Shabani, A Tavakoli, S H Hekmatimoghaddam, A Sarli, H Azizi, P Izadi and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Targeting Cancer Stem Cells to Overcome Chemoresistance.International journal of molecular sciences · 2018
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 2 countries.

M A ZaimyDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
A JebaliAdvanced Medical Sciences and Technologies Department, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
B BazrafshanMedical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
S MehrtashfarDepartment of Biology, Faculty of Basic Sciences, University of Guilan, Rasht, Iran.
S ShabaniDepartment of Biology, Faculty of Science, Zabol University, Zabol, Iran.
A TavakoliDepartment of Molecular Genetics, Science and Research Branch, Islamic Azad University, Zanjan, Iran.
S H HekmatimoghaddamAdvanced Medical Sciences and Technologies Department, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
A SarliDepartment of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
H AziziDepartment of Medical Parasitology, Zabol University of Medical Sciences, Zabol, Iran.
P IzadiDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
B KazemiDepartment of Biotechnology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
A ShojaeiDepartment of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
A AbdalaianDepartment of Chemical Engineering, Princeton University, Princeton, NJ, USA.
J Tavakkoly-BazzazDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRShahid Sadoughi University of Medical Sciences and Health Services · IRGolestan University of Medical Sciences · IRIran University of Medical Sciences · IRIslamic Azad University, Science and Research Branch · IRPrinceton University · USShahid Beheshti University of Medical Sciences · IRTarbiat Modares University · IRUniversity of Guilan · IRZabol University · IRZabol University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to evaluate an engineered nanostructure to silence five important oncogenes, including BAG1, MDM2, Bcl-2, BIRC5 (survivin) and XIAP, in acute myeloid leukemia subtype 2 (AML-M2). The smart nanostructures were functionalized gold nanoparticles (FGNs) containing five antisense oligonucleotides (AOs) and one anti-CD33(+)/CD34(+) aptamer. First, the best AO for each gene was selected with the OligoWalk online software, and then different arrangements of AOs were evaluated with the RNAstructure software. Thereafter, naked gold nanoparticles (NGNs) were synthesized by the reaction of 1000 mm HAuCl4 with 10 μg ml(-1) ascorbic acid. Next, five AOs and one anti-CD33(+)/CD34(+) aptamer were attached to NGNs through serial reactions. Later, 5 ml of heparinized blood samples from five AML-M2 patients were prepared, cancerous cells were isolated and then incubated with three concentrations (75, 150 and 300 μg ml(-1)) each of FGNs, NGNs, gold nanoparticles functionalized with scrambled oligonucleotides (GNFSONs) and doxorubicin. Finally, cell death percentage and gene expressions were measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and real-time PCR, respectively. This study showed that FGNs and doxorubicin led to more cell death compared with NGNs and GNFSONs (P<0.05). Interestingly, all concentrations of FGNs led to a decrease in gene expression. As an important finding, although all concentrations of doxorubicin could also inhibit the expression of genes, FGNs had more effect (P<0.05). Moreover, both NGNs and GNFSONs could silence all genes only at a concentration of 300 μg ml(-1). For BCL2 and XIAP, a dose-dependent pattern was observed, but there was no similar pattern for others.

Indexed as

Gene ExpressionMetal NanoparticlesAntigens, CD34Antineoplastic AgentsAptamers, NucleotideBiomarkers, TumorCell Line, TumorGoldHumansLeukemia, Myeloid, AcuteOligonucleotides, AntisenseSialic Acid Binding Ig-like Lectin 3Antigens, CD34Antineoplastic AgentsAptamers, NucleotideBiomarkers, TumorCD33 protein, humanGoldOligonucleotides, AntisenseSialic Acid Binding Ig-like Lectin 3

Identifiers

PMID27514505
OpenAlexW2513863672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.